Malaria a major public health issue

What Sanofi does…

Despite significant multisectoral efforts, malaria remains a challenge in many endemic countries.

For decades, Sanofi has played a key role in fighting malaria in low and middle-income countries with a comprehensive range of drugs and efficient disease awareness programs. 

Sanofi’s activities include:

• Supply of an hemi-synthetic quality assured artemisinin combination therapy (ACT) with a sustainable  pricing and safety stock for all patients with uncomplicated Plasmodium falciparum malaria infection.  Since 2007, we have already provided more than 530 million treatments.
• Development of a primaquine formulation suitable for children.
• Supply of the first prequalified artemether injectable for patients with severe malaria not having access  to first line treatment.
• Strengthening of disease awareness efforts with innovative and efficient programs and tools targeting  children.

Because today’s children are tomorrow’s adults, educating them is an effective means of fighting malaria. Too many people, particularly children, are still unaware of the link between a mosquito and malaria. This is why we have developed MOSKI® awareness materials to explain the key actions to take to prevent and treat malaria. Children can also play an active role in prevention campaigns designed to achieve the behavioral change needed to roll back the disease and become advocates for their families and communities.